| NCT ID | NCT05711446 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Weill Medical College of Cornell University |
| Condition | Urinary Tract Infections |
| Study Type | INTERVENTIONAL |
| Enrollment | 438 participants |
| Start Date | 2023-04-07 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 438 participants in total. It began in 2023-04-07 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Urinary tract infections (UTI) are common in kidney transplant recipients and are an important cause of illness and hospital admissions. Past studies have shown that about 1 out of 5 of newly transplanted patients develop UTI within their first 3 months of transplantation. Such UTIs increase the risk for blood stream infection and acute rejection of the kidney, Improvements in urinary voiding techniques may reduce the frequency of UTI. The purpose of this study is to evaluate the benefits of "double voiding" in kidney transplant recipients.
Eligibility Criteria
Inclusion Criteria: * All adult kidney transplant recipients who undergo routine follow-up at the New York Presbyterian - Weill Cornell Medicine (NYP-WCM) Transplant Clinic. Exclusion Criteria: * Kidney transplant recipients who are discharged after a transplant with an indwelling catheter (Foley)
Contact & Investigator
Muthukumar Thangamani, M.D.
PRINCIPAL INVESTIGATOR
Weill Medical College of Cornell University
Frequently Asked Questions
Who can join the NCT05711446 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Urinary Tract Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05711446 currently recruiting?
Yes, NCT05711446 is actively recruiting participants. Contact the research team at mut9002@med.cornell.edu for enrollment information.
Where is the NCT05711446 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05711446 clinical trial?
NCT05711446 is sponsored by Weill Medical College of Cornell University. The principal investigator is Muthukumar Thangamani, M.D. at Weill Medical College of Cornell University. The trial plans to enroll 438 participants.